Vaxart, Inc. (VXRT)
For informational purposes only. Not financial advice.
Vaxart, Inc. (VXRT) is a publicly traded company trading at $0.80 with a market cap of 193M. It holds a high conviction AI score of 75/100 based on fundamental, technical, and sentiment analysis.
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines. Their proprietary oral vaccine platform aims to revolutionize vaccine delivery and efficacy.
Company Overview
Vaxart is pioneering oral recombinant protein vaccines, offering a needle-free alternative with potential for improved efficacy and broader accessibility. With a diverse pipeline targeting norovirus, influenza, RSV, and coronavirus, Vaxart aims to disrupt the traditional vaccine market and address unmet medical needs.
Investment Thesis
Vaxart presents a compelling investment opportunity due to its innovative oral vaccine platform and diverse pipeline targeting prevalent infectious diseases. The potential for needle-free vaccine administration offers a significant competitive advantage, potentially improving patient compliance and reducing healthcare costs. Positive Phase II clinical trial results for its influenza and coronavirus vaccines could serve as major catalysts, driving investor interest and stock appreciation. With a market capitalization of $0.14 billion and a gross margin of 100.0%, Vaxart offers significant upside potential if its clinical programs are successful. The company's focus on mucosal immunity could also lead to more effective vaccines compared to traditional injectable options, further enhancing its value proposition.
Key Highlights
- Market Cap of $0.14 billion reflects the company's growth potential in the vaccine market.
- Gross Margin of 100.0% indicates efficient production and cost management.
- Phase II clinical trials underway for coronavirus and influenza vaccines represent key milestones and potential value inflection points.
- Proprietary oral vaccine platform offers a differentiated approach compared to traditional injectable vaccines.
- Beta of 1.25 suggests higher volatility compared to the overall market.
Competitors
Strengths
- Innovative oral vaccine platform.
- Diverse pipeline targeting multiple infectious diseases.
- Potential for improved patient compliance with needle-free administration.
- Strong intellectual property portfolio.
Weaknesses
- Clinical-stage company with no currently marketed products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
- High beta indicates greater stock price volatility.
Catalysts
- Upcoming: Phase II clinical trial results for coronavirus vaccine.
- Upcoming: Phase Ib clinical trial results for norovirus vaccine.
- Ongoing: Advancement of RSV vaccine program.
- Ongoing: Potential partnerships with pharmaceutical companies.
- Ongoing: Grant funding opportunities for vaccine development.
Risks
- Potential: Clinical trial failures could significantly impact stock price.
- Potential: Competition from larger pharmaceutical companies with greater resources.
- Potential: Regulatory delays in vaccine approval process.
- Ongoing: Dependence on external funding for research and development.
- Ongoing: High beta indicates greater stock price volatility.
Growth Opportunities
- Norovirus Vaccine Development: Vaxart's oral norovirus vaccine, currently in Phase Ib clinical trials, addresses a significant unmet need. Norovirus is a leading cause of gastroenteritis worldwide, and an effective vaccine could capture a substantial market share. The global market for norovirus vaccines is projected to reach hundreds of millions of dollars, offering a significant revenue opportunity for Vaxart upon successful commercialization. Timeline for potential market entry is estimated within the next 3-5 years, pending successful trial outcomes.
- Influenza Vaccine Advancement: The seasonal influenza vaccine market is a large and established market, but Vaxart's oral influenza vaccine offers a differentiated product with potential advantages in terms of ease of administration and improved immune response. Positive Phase II clinical trial results could pave the way for Phase III trials and eventual commercialization. Capturing even a small percentage of this multi-billion dollar market could significantly boost Vaxart's revenue.
- Coronavirus Vaccine Program: Vaxart's oral coronavirus vaccine program represents a significant growth opportunity, particularly as the virus continues to mutate and new variants emerge. An oral vaccine could offer advantages in terms of distribution and administration, especially in resource-limited settings. Successful completion of Phase II trials and subsequent commercialization could generate substantial revenue for Vaxart, addressing a global health need.
- RSV Vaccine Development: Respiratory syncytial virus (RSV) is a common respiratory virus that can cause severe illness in infants and older adults. Vaxart's RSV vaccine program aims to develop an effective oral vaccine to prevent RSV infection. The RSV vaccine market is expected to grow significantly in the coming years, driven by increasing awareness and the development of new vaccines. Vaxart's oral vaccine platform could offer a competitive advantage in this market.
- Therapeutic HPV Vaccine: Vaxart is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus (HPV). This represents a longer-term growth opportunity, as therapeutic cancer vaccines are a rapidly evolving field. Successful development of an effective HPV vaccine could generate significant revenue and address a critical unmet medical need.
Opportunities
- Partnerships with pharmaceutical companies for commercialization.
- Expansion of pipeline to address additional infectious diseases.
- Government funding and grants for vaccine development.
- Growing demand for convenient and effective vaccines.
Threats
- Clinical trial failures.
- Competition from established vaccine manufacturers.
- Regulatory hurdles and approval delays.
- Patent challenges and intellectual property infringement.
Competitive Advantages
- Proprietary oral vaccine platform technology.
- Patent protection for vaccine formulations and delivery methods.
- Clinical trial data demonstrating safety and efficacy.
- Potential for mucosal immunity with oral vaccines.
About
Vaxart, Inc., headquartered in South San Francisco, California, is a clinical-stage biotechnology company dedicated to transforming vaccine administration through its innovative oral recombinant protein vaccine platform. The company was founded with the vision of creating more convenient, effective, and accessible vaccines that can be administered without injections. Vaxart's proprietary technology utilizes oral tablet vaccines, designed to stimulate a broad immune response, including mucosal immunity, which is often lacking in traditional injectable vaccines. The company's product pipeline is focused on addressing significant global health challenges. Key programs include a norovirus vaccine, currently in Phase Ib clinical trials, targeting both GI.1 and GII.4 norovirus strains. Vaxart is also developing a seasonal influenza vaccine, which has completed Phase II clinical trials, and vaccines for respiratory syncytial virus (RSV) and coronavirus (SARS-CoV-2), both in Phase II clinical trials. Additionally, Vaxart is exploring therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus (HPV). Vaxart's commitment to innovation and its unique oral vaccine platform position it as a potential disruptor in the vaccine industry.
What They Do
- Develop oral recombinant protein vaccines.
- Utilize a proprietary oral vaccine platform.
- Target norovirus with an oral tablet vaccine in Phase Ib clinical trials.
- Develop a seasonal influenza vaccine in Phase II clinical trials.
- Create vaccines for respiratory syncytial virus (RSV).
- Develop a coronavirus vaccine in Phase II clinical trials.
- Explore therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Business Model
- Develop and patent novel oral vaccine technologies.
- Conduct clinical trials to demonstrate safety and efficacy.
- Partner with pharmaceutical companies for commercialization and distribution.
- Generate revenue through licensing agreements and product sales.
Industry Context
Vaxart operates in the competitive biotechnology industry, specifically within the vaccine market. The global vaccine market is experiencing substantial growth, driven by increasing awareness of preventative healthcare, rising incidence of infectious diseases, and advancements in vaccine technology. Key players include established pharmaceutical giants and emerging biotech companies. Vaxart's oral vaccine platform differentiates it from competitors, offering a potential advantage in terms of ease of administration and improved immune response. The company competes with firms like Arbutus Biopharma Corporation (ACRV), and other companies developing novel vaccine technologies.
Key Customers
- Pharmaceutical companies seeking innovative vaccine technologies.
- Healthcare providers looking for convenient and effective vaccines.
- Government agencies and public health organizations.
- Patients seeking needle-free vaccine options.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $5M | -$14M | $-0.06 |
| Q4 2024 | $15M | -$12M | $0.00 |
| Q1 2025 | $21M | -$16M | $-0.07 |
| Q2 2025 | $40M | -$15M | $-0.07 |
Source: Company filings
Chart & Info
Price Chart
Vaxart, Inc. (VXRT) stock price: $0.80 (+0.05, +6.67%)
Why Bull
- •Recent insider buying suggests confidence in Vaxart's potential, indicating that key stakeholders believe in the company's future prospects.
- •Community sentiment has shown a notable increase in optimism, particularly around Vaxart's innovative oral vaccine platform, which could transform vaccine delivery.
- •Positive developments in partnerships and collaborations have emerged, indicating a growing interest from larger entities in Vaxart's technology.
- •The overall market perception is leaning towards a recovery in biotech stocks, with Vaxart positioned to benefit from this trend.
Why Bear
- •Concerns remain about the pace of Vaxart's product development, with some investors questioning the timeline for clinical trial results.
- •Social sentiment has been mixed, with some community members expressing skepticism about the company's ability to compete in a crowded vaccine market.
- •Recent regulatory hurdles have raised doubts among investors, leading to a cautious outlook on Vaxart's future approvals.
- •The volatility in the biotech sector has created a bearish undertone, with many traders wary of potential downturns in stock performance.
Latest News
No recent news available for VXRT.
Technical Analysis
Rationale
AI-generated technical analysis for VXRT including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Vaxart, Inc. (VXRT) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for VXRT.
Make a Prediction
Set your price target for Vaxart, Inc. (VXRT), choose a timeframe, and track your prediction accuracy.
Current price: $0.80
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VXRT.
Price Targets
Median: $2.00 (+150.0% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 10/100
Revenue surged 288.9% year-over-year, indicating explosive demand and rapid market share expansion.
-
Gross Margin 10/100
Gross margin of 100.0% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Limited cash of $25M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 10/100
Investing 258.6% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 7/100
Lower turnover at 0.21% means fewer daily trades, which may widen bid-ask spreads.
-
Price Momentum 6/100
Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.
-
News Sentiment 5/100
News sentiment is mixed, with a balance of positive and negative coverage in recent days.
What does this score mean?
The MoonshotScore rates VXRT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Frequently Asked Questions
What does Vaxart, Inc. do?
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing and commercializing oral recombinant protein vaccines. The company's proprietary oral vaccine platform aims to revolutionize vaccine delivery by offering a needle-free alternative to traditional injectable vaccines. Vaxart's pipeline includes vaccines targeting norovirus, influenza, RSV, and coronavirus. By focusing on oral administration and mucosal immunity, Vaxart seeks to improve vaccine efficacy, patient compliance, and global accessibility, positioning itself as a potential disruptor in the vaccine market.
Is VXRT stock a good buy?
VXRT stock presents a speculative investment opportunity with significant potential upside and inherent risks. The company's innovative oral vaccine platform and diverse pipeline offer compelling growth prospects, particularly if clinical trials are successful. However, as a clinical-stage company with no currently marketed products, Vaxart's value is heavily dependent on positive clinical trial outcomes and regulatory approvals. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in VXRT stock, weighing the potential rewards against the inherent uncertainties of biotechnology investments.
What are the main risks for VXRT?
The main risks for Vaxart include clinical trial failures, competition from established vaccine manufacturers, regulatory hurdles, and reliance on external funding. Clinical trial failures could significantly impact the company's valuation and future prospects. Competition from larger pharmaceutical companies with greater resources poses a significant challenge. Regulatory delays in the vaccine approval process could also hinder Vaxart's progress. Additionally, the company's dependence on external funding for research and development creates financial risk.
Is VXRT a good stock to buy?
Whether VXRT is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Vaxart, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice.
What is the VXRT MoonshotScore?
The MoonshotScore rates VXRT from 0 to 100 across growth potential, financial health, market momentum, and risk factors. Scores above 70 suggest strong potential, 50-70 moderate, and below 50 warrants caution. It is recalculated daily using the latest market data. This score is informational only.
How often is VXRT data updated?
VXRT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What do analysts say about VXRT?
Analyst coverage for VXRT includes consensus ratings (buy, hold, sell), 12-month price targets, and earnings estimates from major research firms. Key data points: consensus target price, number of covering analysts, recent upgrades or downgrades, and earnings beat/miss history. See the Analyst Consensus section on this page.
What are the risks of investing in VXRT?
Risk categories for VXRT include market risk, company-specific risk (management, competition), financial risk (debt, cash burn), and macroeconomic risk (rates, inflation). Beta above 1.0 indicates higher volatility than the S&P 500. Review the Risk Factors section on this page for details. All investments carry risk of loss.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment in biotechnology companies is inherently risky.
- This analysis is for informational purposes only and does not constitute financial advice.